DCIS Patients' Risk of Dying From Cardiovascular Disease
Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.
Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.
A large study in the Netherlands found that women who had received radiation therapy to treat DCIS had no increased risk of cardiovascular disease compared to the general population of Dutch women, nor compared to DCIS patients treated with surgery only.
In addition, researchers found that after a median follow-up of 10 years, DCIS survivors had 30% lower risk of dying from cardiovascular disease compared to the general population of Dutch women.
Clinical Pearls
Boekel theorizes that this could be because DCIS patients adapted their lifestyle after diagnosis, or that there are conflicting risk factors between DCIS and cardiovascular disease (such as age of menopause). Thirdly, there could be a difference in health consciousness between DCIS patients and the general population -- DCIS patients could be generally more health conscious, which is why they went into a screening program and were diagnosed with DCIS, Boekel says.Researchers have several theories about why patients with DCIS had a lower risk of dying from cardiovascular disease:
- Patients adapted their lifestyle following DCIS diagnosis
- Conflicting risk factors exist between DCIS and cardiovascular disease
- Difference in health consciousness between DCIS patients and the general population
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
